Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain can… Read more
Northwest Biotherapeutics Inc (NWBO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.128x
Based on the latest financial reports, Northwest Biotherapeutics Inc (NWBO) has a cash flow conversion efficiency ratio of 0.128x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.89 Million) by net assets ($-108.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Northwest Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Northwest Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Northwest Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Northwest Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diversified Royalty Corp
PINK:BEVFF
|
0.046x |
|
Zhejiang Yasha Decoration Co Ltd
SHE:002375
|
-0.009x |
|
Changzhou Almaden Co Ltd
SHE:002623
|
-0.016x |
|
Shenzhen AV-Display Co. Ltd.
SHE:300939
|
0.017x |
|
Shandong Jinling Mining Co Ltd
SHE:000655
|
0.023x |
|
Hidili Industry International Development Limited
PINK:HIIDQ
|
0.024x |
|
Nichidenbo Corp
TW:3090
|
0.017x |
|
World Acceptance Corporation
NASDAQ:WRLD
|
468580.927x |
Annual Cash Flow Conversion Efficiency for Northwest Biotherapeutics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Northwest Biotherapeutics Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-94.49 Million | $-57.02 Million | 0.603x | -26.00% |
| 2023-12-31 | $-65.77 Million | $-53.64 Million | 0.815x | +97.95% |
| 2022-12-31 | $-128.10 Million | $-52.77 Million | 0.412x | +33.37% |
| 2021-12-31 | $-123.99 Million | $-38.30 Million | 0.309x | +249.33% |
| 2020-12-31 | $-362.95 Million | $-32.09 Million | 0.088x | -87.91% |
| 2019-12-31 | $-43.57 Million | $-31.86 Million | 0.731x | -0.29% |
| 2018-12-31 | $-47.16 Million | $-34.59 Million | 0.733x | -4.96% |
| 2017-12-31 | $-47.29 Million | $-36.49 Million | 0.772x | -63.26% |
| 2016-12-31 | $-26.50 Million | $-55.65 Million | 2.100x | -87.51% |
| 2015-12-31 | $-4.68 Million | $-78.61 Million | 16.811x | +978.93% |
| 2014-12-31 | $-35.03 Million | $-54.58 Million | 1.558x | -96.27% |
| 2013-12-31 | $-905.00K | $-37.80 Million | 41.768x | +828.10% |
| 2012-12-31 | $-5.06 Million | $-22.75 Million | 4.500x | +1496.51% |
| 2011-12-31 | $-52.17 Million | $-14.71 Million | 0.282x | -- |